C. Desmet et al., THE ACTIVATION OF HUMAN GENE MAGE-1 IN TUMOR-CELLS IS CORRELATED WITHGENOME-WIDE DEMETHYLATION, Proceedings of the National Academy of Sciences of the United Statesof America, 93(14), 1996, pp. 7149-7153
Human gene MAGE-1 encodes tumor-specific antigens that are recognized
on melanoma cells by autologous cytolytic T lymphocytes. This gene is
expressed in a significant proportion of tumors of various histologica
l types, but not in normal tissues except male germ-line cells. We rep
orted previously that reporter genes driven by the MAGE-1 promoter are
active not only in the tumor cell lines that express MAGE-1 but also
in those that do not. This suggests that the critical factor causing t
he activation of MAGE-1 in certain tumors is not the presence of the a
ppropriate transcription factors. The two major MAGE-1 promoter elemen
ts have an Ets binding site, which contains a CpG dinucleotide. We rep
ort here that these CpG are demethylated in the tumor cell lines that
express MAGE-1, and are methylated in those that do not express the ge
ne. Methylation of these CpG inhibits the binding of transcription fac
tors, as seen by mobility shift assay. Treatment with the demethylatin
g agent 5-aza-2'-deoxycytidine activated gene MAGE-1 not only in tumor
cell lines but also in primary fibroblasts. Finally, the overall leve
l of CpG methylation was evaluated in 20 different tumor cell lines. I
t was inversely correlated with the expression of MAGE-1. We conclude
that the activation of MAGE-1 in cancer cells is due to the demethylat
ion of the promoter. This appears to be a consequence of a genome-wide
demethylation process that occurs in many cancers and is correlated w
ith tumor progression.